FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1489421422> ?p ?o ?g. }

• W1489421422 endingPage "84" @default.
• W1489421422 startingPage "6876" @default.
• W1489421422 abstract "Specific phosphorylation of serine- and arginine-rich pre-mRNA splicing factors (SR proteins) is one of the key determinants regulating splicing events. Several kinases involved in SR protein phosphorylation have been identified and characterized, among which human DNA topoisomerase I is known to have DNA-relaxing activity. In this study, we have investigated the mechanism of splicing inhibition by a glycosylated indolocarbazole derivative (NB-506), a potent inhibitor of both kinase and relaxing activities of topoisomerase I. NB-506 completely inhibits the capacity of topoisomerase I to phosphorylate, in vitro, the human splicing factor 2/alternative splicing factor (SF2/ASF). This inhibition is specific, because NB-506 does not demonstrate activity against other kinases known to phosphorylate SF2/ASF such as SR protein kinase 1 and cdc2 kinase. Importantly, HeLa nuclear extracts competent in splicing but not splicing-deficient cytoplasmic S100 extracts treated with the drug fail to phosphorylate SF2/ASF and to support splicing of pre-mRNA substrates containing SF2/ASF-target sequences. Native gel analysis of splicing complexes revealed that the drug affects the formation of the spliceosome, a dynamic ribonucleoprotein structure where splicing takes place. In the presence of the drug, neither pre-spliceosome nor spliceosome is formed, demonstrating that splicing inhibition occurs at early steps of spliceosome assembly. Splicing inhibition can be relieved by adding phosphorylated SF2/ASF, showing that extracts treated with NB-506 lack a phosphorylating activity required for splicing. Moreover, NB-506 has a cytotoxic effect on murine P388 leukemia cells but not on P388CPT5 camptothecin-resistant cells that carry two point mutations in conserved regions of topoisomerase I gene (Gly361Val and Asp709Tyr). After drug treatment, P388 cells accumulated hypophosphorylated forms of SR proteins and polyadenylated RNA in the nucleus. In contrast, neither SR protein phosphorylation nor polyadenylated mRNA distribution was affected in P388 CPT5-treated cells. Consistently, NB506 treatment altered the mRNA levels and/or splicing pattern of several tested genes (Bcl-X, CD 44, SC35, and Sty) in P388 cells but not in P388 CPT5 cells. The study shows for the first time that indolocarbazole drugs targeting topoisomerase I can affect gene expression by modulating pre-mRNA splicing through inhibition of SR proteins phosphorylation." @default.
• W1489421422 created "2016-06-24" @default.
• W1489421422 creator A5013576274 @default.
• W1489421422 creator A5027191978 @default.
• W1489421422 creator A5038717819 @default.
• W1489421422 creator A5046805097 @default.
• W1489421422 creator A5060967024 @default.
• W1489421422 creator A5061303690 @default.
• W1489421422 creator A5073920505 @default.
• W1489421422 date "2001-09-15" @default.
• W1489421422 modified "2023-10-14" @default.
• W1489421422 title "Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506." @default.
• W1489421422 cites W1497147128 @default.
• W1489421422 cites W1516505305 @default.
• W1489421422 cites W1576983306 @default.
• W1489421422 cites W1969433341 @default.
• W1489421422 cites W1969762229 @default.
• W1489421422 cites W1973916539 @default.
• W1489421422 cites W1976226375 @default.
• W1489421422 cites W1991082995 @default.
• W1489421422 cites W2012827002 @default.
• W1489421422 cites W2014427312 @default.
• W1489421422 cites W2025007043 @default.
• W1489421422 cites W2029194790 @default.
• W1489421422 cites W2029853063 @default.
• W1489421422 cites W2043300583 @default.
• W1489421422 cites W2061169749 @default.
• W1489421422 cites W2063176993 @default.
• W1489421422 cites W2069740830 @default.
• W1489421422 cites W2075289068 @default.
• W1489421422 cites W2082084396 @default.
• W1489421422 cites W2084043967 @default.
• W1489421422 cites W2091129135 @default.
• W1489421422 cites W2094972420 @default.
• W1489421422 cites W2099184569 @default.
• W1489421422 cites W2110090133 @default.
• W1489421422 cites W2113262303 @default.
• W1489421422 cites W2115597318 @default.
• W1489421422 cites W2116764585 @default.
• W1489421422 cites W2116884417 @default.
• W1489421422 cites W2126825296 @default.
• W1489421422 cites W2132505931 @default.
• W1489421422 cites W2142122497 @default.
• W1489421422 cites W2143889483 @default.
• W1489421422 cites W2149565889 @default.
• W1489421422 cites W2155223361 @default.
• W1489421422 cites W2157713791 @default.
• W1489421422 cites W2160635170 @default.
• W1489421422 cites W2169453421 @default.
• W1489421422 cites W2152989464 @default.
• W1489421422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11559564" @default.
• W1489421422 hasPublicationYear "2001" @default.
• W1489421422 type Work @default.
• W1489421422 sameAs 1489421422 @default.
• W1489421422 citedByCount "52" @default.
• W1489421422 countsByYear W14894214222012 @default.
• W1489421422 countsByYear W14894214222013 @default.
• W1489421422 countsByYear W14894214222014 @default.
• W1489421422 countsByYear W14894214222015 @default.
• W1489421422 countsByYear W14894214222016 @default.
• W1489421422 countsByYear W14894214222017 @default.
• W1489421422 countsByYear W14894214222018 @default.
• W1489421422 countsByYear W14894214222020 @default.
• W1489421422 countsByYear W14894214222021 @default.
• W1489421422 countsByYear W14894214222022 @default.
• W1489421422 countsByYear W14894214222023 @default.
• W1489421422 crossrefType "journal-article" @default.
• W1489421422 hasAuthorship W1489421422A5013576274 @default.
• W1489421422 hasAuthorship W1489421422A5027191978 @default.
• W1489421422 hasAuthorship W1489421422A5038717819 @default.
• W1489421422 hasAuthorship W1489421422A5046805097 @default.
• W1489421422 hasAuthorship W1489421422A5060967024 @default.
• W1489421422 hasAuthorship W1489421422A5061303690 @default.
• W1489421422 hasAuthorship W1489421422A5073920505 @default.
• W1489421422 hasConcept C104317684 @default.
• W1489421422 hasConcept C10447831 @default.
• W1489421422 hasConcept C105580179 @default.
• W1489421422 hasConcept C11960822 @default.
• W1489421422 hasConcept C184235292 @default.
• W1489421422 hasConcept C194583182 @default.
• W1489421422 hasConcept C40000846 @default.
• W1489421422 hasConcept C42576000 @default.
• W1489421422 hasConcept C54458228 @default.
• W1489421422 hasConcept C55493867 @default.
• W1489421422 hasConcept C67705224 @default.
• W1489421422 hasConcept C69551769 @default.
• W1489421422 hasConcept C73758832 @default.
• W1489421422 hasConcept C86803240 @default.
• W1489421422 hasConcept C95444343 @default.
• W1489421422 hasConceptScore W1489421422C104317684 @default.
• W1489421422 hasConceptScore W1489421422C10447831 @default.
• W1489421422 hasConceptScore W1489421422C105580179 @default.
• W1489421422 hasConceptScore W1489421422C11960822 @default.
• W1489421422 hasConceptScore W1489421422C184235292 @default.
• W1489421422 hasConceptScore W1489421422C194583182 @default.
• W1489421422 hasConceptScore W1489421422C40000846 @default.
• W1489421422 hasConceptScore W1489421422C42576000 @default.
• W1489421422 hasConceptScore W1489421422C54458228 @default.

• next